search
Back to results

A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies. (PIVOINE)

Primary Purpose

Fibrodysplasia Ossificans Progressiva (FOP)

Status
Active
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Palovarotene
Sponsored by
Ipsen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fibrodysplasia Ossificans Progressiva (FOP)

Eligibility Criteria

14 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Participant has completed the EOS or End of Treatment Visit of Study PVO-1A-301 or PVO-1A-202 (PVO-1A-202 Parts C and D correspond to Study PVO-1A-204 in France) and did not previously withdraw consent from any of the parent studies to be eligible for Study CLIN-60120-452.
  • Participant must be ≥14 years of age (aligned with the age of treated participants in the ongoing parent studies PVO-1A-301 and PVO-1A-202/PVO-1A-204) and qualify as 100% skeletally mature (if <18 years, based on assessments carried out at parent EOS Visit; if ≥18 years, automatically considered 100% skeletally mature) or have reached final adult height based on investigator's assessment, at the time the Study CLIN- 60120-452 informed consent is signed.

Exclusion Criteria:

  • History of allergy or hypersensitivity to retinoids, gelatin, lactose (note that lactose intolerance is not exclusionary) or palovarotene, or unresponsiveness to prior treatment with palovarotene.
  • Uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric, or other significant disease.
  • Symptomatic vertebral fracture.
  • Intercurrent known or suspected non-healed fracture at any location;
  • Any other medical condition/clinically significant abnormalities that would expose the participant to undue risk or interfere with study assessments.
  • Amylase or lipase >2× above the upper limit of normal (ULN) or with a history of chronic pancreatitis.
  • Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5× ULN.
  • Fasting triglycerides >400 mg/dL with or without therapy.
  • Suicidal ideation (type 4 or 5) or any suicidal behaviour at the Inclusion Visit as defined by the Columbia-Suicide Severity Rating Scale (C-SSRS).
  • Current use of vitamin A or beta carotene, multivitamins containing vitamin A or beta carotene, or herbal preparations, fish oil, and unable or unwilling to discontinue use of these products during palovarotene treatment.
  • Exposure to synthetic oral retinoids other than palovarotene within 4 weeks of the Inclusion Visit.
  • Concurrent treatment with tetracycline or any tetracycline derivatives due to the potential increased risk of pseudotumor cerebri.
  • Use of concomitant medications that are strong inhibitors or inducers of cytochrome P450 (CYP450) 3A4 activity; or kinase inhibitors such as imatinib.
  • Palovarotene is reimbursed in the country where the study is being conducted.
  • Any reason that, in the opinion of the investigator, would lead to the inability of the participant and/or family to comply with the protocol.

Sites / Locations

  • University of California San Francisco (UCSF)
  • Mayo Clinic
  • Children's Hospital of Philidelphia
  • The Perelman School of Medicine - The University of Pennsylvania
  • Hospital Italiano de Buenos Aires
  • Royal North Shore Hospital
  • Hospital Israelita Albert Einstein
  • Toronto General Hospital
  • Groupe Hospitalier Necker Enfants Malades
  • Istituto Giannina Gaslini
  • Hospital Universitario Ramon y Cajal
  • Norrlands Universitetssjukhus
  • Royal National Orthopaedic Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Palovarotene Chronic/Flare-Up Regimen

Arm Description

Chronic treatment: participants will receive 5 mg palovarotene or the dose received during participation in the parent study at the time of transition to Study CLIN-60120-452 or prior to interrupting/stopping palovarotene treatment. Flare-up treatment: at the time of a flare-up (or substantial high-risk traumatic event likely to lead to a flare-up) participants will receive 20 mg palovarotene for 28 days, followed by 10 mg palovarotene for 56 days.

Outcomes

Primary Outcome Measures

Incidence and description of all serious and non-serious treatment-emergent adverse events (TEAEs) whether or not they are considered as related to the study intervention;
Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and will be classified by PT (Preferred Term) and SOC (System Organ Class)

Secondary Outcome Measures

Raw values and change from the Inclusion Visit in CAJIS (Cumulative Analogue Joint Involvement Scale) total score
Raw values and shift from the Inclusion Visit in the use of assistive devices and adaptations for daily living
The use of assistive devices and adaptations for daily living will be collected using the FOP assistive devices assessment.
Raw values and change from the Inclusion Visit in % of worst score for total score, upper extremities subscore and mobility subscore
Using the adult form of the FOP-PFQ (FOP-Physical Function Questionnaire) for all participants
Frequency of healthcare services utilization
Raw values and change from the Inclusion Visit in observed and % predicted FVC (Forced Vital Capacity)
Raw values and change from the Inclusion Visit in observed and % predicted FEV1 (Forced Expiratory Volume in One Second)
Raw values and change from the Inclusion Visit in absolute and % predicted FEV1/FVC ratio
Raw values and change from the Inclusion Visit in observed and % predicted DLCO (Diffusion Capacity of the Lung for Carbon Monoxide)
Raw values and change from the Inclusion Visit in physical and mental function (mean global physical and mental health score converted into T-scores)
Using the adult form of the PROMIS (Patient Reported Outcomes Measurement Information System) Global Health Scale for all participants
Raw values and change from the Inclusion Visit in number of investigator-reported flareups, flare-up outcomes (new bone growth, restricted movement) and flare-up duration by body location and overall;
Percentage of participants with new bone growth overall and by flare-up status

Full Information

First Posted
August 25, 2021
Last Updated
September 29, 2023
Sponsor
Ipsen
search

1. Study Identification

Unique Protocol Identification Number
NCT05027802
Brief Title
A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.
Acronym
PIVOINE
Official Title
Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed Study PVO-1A-301 or PVO-1A-202/PVO-1A-204 and May Benefit From Palovarotene Therapy.
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
March 14, 2022 (Actual)
Primary Completion Date
November 29, 2024 (Anticipated)
Study Completion Date
January 3, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ipsen

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The main objective of this study is to further evaluate the safety and efficacy of palovarotene in adult and paediatric participants with FOP. The aim of the study is also to ensure treatment continuity to participants who have completed one of the parent studies (Study PVO-1A-301, Study PVO-1A-202 and Study PVO-1A-204) and who, in the investigator's judgement, may benefit from palovarotene therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fibrodysplasia Ossificans Progressiva (FOP)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
61 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Palovarotene Chronic/Flare-Up Regimen
Arm Type
Experimental
Arm Description
Chronic treatment: participants will receive 5 mg palovarotene or the dose received during participation in the parent study at the time of transition to Study CLIN-60120-452 or prior to interrupting/stopping palovarotene treatment. Flare-up treatment: at the time of a flare-up (or substantial high-risk traumatic event likely to lead to a flare-up) participants will receive 20 mg palovarotene for 28 days, followed by 10 mg palovarotene for 56 days.
Intervention Type
Drug
Intervention Name(s)
Palovarotene
Intervention Description
Palovarotene will be taken orally once daily at approximately the same time each day.
Primary Outcome Measure Information:
Title
Incidence and description of all serious and non-serious treatment-emergent adverse events (TEAEs) whether or not they are considered as related to the study intervention;
Description
Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and will be classified by PT (Preferred Term) and SOC (System Organ Class)
Time Frame
Three years.
Secondary Outcome Measure Information:
Title
Raw values and change from the Inclusion Visit in CAJIS (Cumulative Analogue Joint Involvement Scale) total score
Time Frame
Every six months up to three years
Title
Raw values and shift from the Inclusion Visit in the use of assistive devices and adaptations for daily living
Description
The use of assistive devices and adaptations for daily living will be collected using the FOP assistive devices assessment.
Time Frame
Every six months up to three years
Title
Raw values and change from the Inclusion Visit in % of worst score for total score, upper extremities subscore and mobility subscore
Description
Using the adult form of the FOP-PFQ (FOP-Physical Function Questionnaire) for all participants
Time Frame
Every six months up to three years
Title
Frequency of healthcare services utilization
Time Frame
Three years
Title
Raw values and change from the Inclusion Visit in observed and % predicted FVC (Forced Vital Capacity)
Time Frame
Every six months up to three years
Title
Raw values and change from the Inclusion Visit in observed and % predicted FEV1 (Forced Expiratory Volume in One Second)
Time Frame
Every six months up to three years
Title
Raw values and change from the Inclusion Visit in absolute and % predicted FEV1/FVC ratio
Time Frame
Every six months up to three years
Title
Raw values and change from the Inclusion Visit in observed and % predicted DLCO (Diffusion Capacity of the Lung for Carbon Monoxide)
Time Frame
Every six months up to three years
Title
Raw values and change from the Inclusion Visit in physical and mental function (mean global physical and mental health score converted into T-scores)
Description
Using the adult form of the PROMIS (Patient Reported Outcomes Measurement Information System) Global Health Scale for all participants
Time Frame
Every six months up to three years
Title
Raw values and change from the Inclusion Visit in number of investigator-reported flareups, flare-up outcomes (new bone growth, restricted movement) and flare-up duration by body location and overall;
Time Frame
Every six months up to three years
Title
Percentage of participants with new bone growth overall and by flare-up status
Time Frame
Every six months up to three years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
14 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participant has completed the EOS or End of Treatment Visit of Study PVO-1A-301 or PVO-1A-202 (PVO-1A-202 Parts C and D correspond to Study PVO-1A-204 in France) and did not previously withdraw consent from any of the parent studies to be eligible for Study CLIN-60120-452. Participant must be ≥14 years of age (aligned with the age of treated participants in the ongoing parent studies PVO-1A-301 and PVO-1A-202/PVO-1A-204) and qualify as 100% skeletally mature (if <18 years, based on assessments carried out at parent EOS Visit; if ≥18 years, automatically considered 100% skeletally mature) or have reached final adult height based on investigator's assessment, at the time the Study CLIN- 60120-452 informed consent is signed. Exclusion Criteria: History of allergy or hypersensitivity to retinoids, gelatin, lactose (note that lactose intolerance is not exclusionary) or palovarotene, or unresponsiveness to prior treatment with palovarotene. Uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric, or other significant disease. Symptomatic vertebral fracture. Intercurrent known or suspected non-healed fracture at any location; Any other medical condition/clinically significant abnormalities that would expose the participant to undue risk or interfere with study assessments. Amylase or lipase >2× above the upper limit of normal (ULN) or with a history of chronic pancreatitis. Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5× ULN. Fasting triglycerides >400 mg/dL with or without therapy. Suicidal ideation (type 4 or 5) or any suicidal behaviour at the Inclusion Visit as defined by the Columbia-Suicide Severity Rating Scale (C-SSRS). Current use of vitamin A or beta carotene, multivitamins containing vitamin A or beta carotene, or herbal preparations, fish oil, and unable or unwilling to discontinue use of these products during palovarotene treatment. Exposure to synthetic oral retinoids other than palovarotene within 4 weeks of the Inclusion Visit. Concurrent treatment with tetracycline or any tetracycline derivatives due to the potential increased risk of pseudotumor cerebri. Use of concomitant medications that are strong inhibitors or inducers of cytochrome P450 (CYP450) 3A4 activity; or kinase inhibitors such as imatinib. Palovarotene is reimbursed in the country where the study is being conducted. Any reason that, in the opinion of the investigator, would lead to the inability of the participant and/or family to comply with the protocol.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ipsen Medical Director
Organizational Affiliation
Ipsen
Official's Role
Study Director
Facility Information:
Facility Name
University of California San Francisco (UCSF)
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
Children's Hospital of Philidelphia
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
The Perelman School of Medicine - The University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Hospital Italiano de Buenos Aires
City
Buenos Aires
ZIP/Postal Code
C1181ACH
Country
Argentina
Facility Name
Royal North Shore Hospital
City
Saint Leonards
State/Province
New South Wales
ZIP/Postal Code
2065
Country
Australia
Facility Name
Hospital Israelita Albert Einstein
City
Morumbi
State/Province
Sao-Paulo
ZIP/Postal Code
05652-900
Country
Brazil
Facility Name
Toronto General Hospital
City
Toronto
ZIP/Postal Code
M5T 2S8
Country
Canada
Facility Name
Groupe Hospitalier Necker Enfants Malades
City
Paris
ZIP/Postal Code
75015
Country
France
Facility Name
Istituto Giannina Gaslini
City
Genoa
ZIP/Postal Code
16147
Country
Italy
Facility Name
Hospital Universitario Ramon y Cajal
City
Colmenar Viejo
ZIP/Postal Code
28034
Country
Spain
Facility Name
Norrlands Universitetssjukhus
City
Umeå
ZIP/Postal Code
90737
Country
Sweden
Facility Name
Royal National Orthopaedic Hospital
City
London
ZIP/Postal Code
HA7 4LP
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants. Any requests should be submitted to www.vivli.org for assessment by an independent scientific review board.
IPD Sharing Time Frame
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and EU or after the primary manuscript describing the results has been accepted for publication, whichever is later.
IPD Sharing Access Criteria
Further details on Ipsen's sharing criteria, eligible studies and process for sharing are available here (https://vivli.org/members/ourmembers/).
IPD Sharing URL
https://vivli.org/members/ourmembers/

Learn more about this trial

A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.

We'll reach out to this number within 24 hrs